United Kingdom: 2025/2026 Policy and Healthcare Snapshot
This page tracks recent UK policy and health-system actions affecting trans people, especially youth access to gender-affirming care.
Last updated: March 2, 2026, 18:14 UTC
Current snapshot
- NHS policy shift (March 12, 2024): NHS England stated puberty-suppressing hormones are no longer a routine commissioning option for under-18s with gender incongruence/gender dysphoria.
- Private prescribing restrictions (May 29, 2024): UK DHSC announced emergency restrictions on private prescribing/supply of puberty blockers for under-18s.
- Indefinite extension (December 11, 2024): UK government announced the private-prescription ban would be made indefinite, with review planned for 2027.
- System-level rationale: The Cass Review remains a core reference for UK restructuring of youth gender services.
Why this matters
These actions narrowed pathways to gender-affirming medication for under-18s, shifting access from routine treatment toward tightly constrained pathways and research contexts.
Sources
- NHS England (March 12, 2024): Clinical policy: puberty suppressing hormones
- UK DHSC (May 29, 2024): New restrictions on puberty blockers
- UK DHSC (December 11, 2024): Ban on puberty blockers to be made indefinite
- Cass Review Final Report (April 10, 2024): Independent Review of Gender Identity Services for Children and Young People